Multiple Catalysts Ahead For Nektar Therapeutics

When I wrote about Nektar Therapeutics (NASDAQ: NKTR ) in April, a major focus of discussion was rezpegaldesleukin and trials of the drug in atopic dermatitis and alopecia areata. Since those trials won't produce data until 2025, I rated the name aScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s D ...